Helix BioPharma
TSX:HBP
C$ 1,95
+ C$0,01 (0,52%)
1,95 C$
+C$0,01 (0,52%)
End-of-day quote: 04/24/2026

Helix BioPharma Stock Value

Analysts currently give TSX:HBP a rating of sf_Data Unavailable.
-

Helix BioPharma Company Info

EPS Growth 5Y
3,04%
Market Cap
C$0,15 B
Long-Term Debt
C$0,00 B
Short Interest
0,44%
Quarterly earnings
03/12/2026
Dividend
C$0,00
Dividend Yield
0,00%
Founded
2008
Industry
Country
ISIN Number

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

There are currently no price targets available for this stock.

In the last five quarters, Helix BioPharma’s Price Target has risen from C$1,70 to C$1,70 - a 0,00% increase.

Top growth stocks in the health care sector (5Y.)

What does Helix BioPharma do?

Helix BioPharma Corp., an immune-oncology company, focuses on the development of cancer drugs in Canada. The company is developing products for the treatment and prevention of cancer based on its proprietary technologies. The company’s product development initiatives are focused primarily on technologies that modulate the tumour microenvironment. The company’s proprietary technology platform, DOS47 has yielded two new drug product candidates, L-DOS47 and V-DOS47. L-DOS47 is under clinical stu...
×